Consequently, studies on drugs used for T2DM in AD found these treatments may represent a promising approach to fight AD, which include MET, GLP-1RA, PPAR-γ agonists, DPP-4i and SGLT2i (Cao et al., 2018). Here, PPARG is linked to type 2 diabetes mellitus.